TY - JOUR AU - Lien, Irvin C. AU - Pollack, Seth M. PY - 2018 TI - Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas JF - Translational Gastroenterology and Hepatology; Vol 3 (January 2018): Translational Gastroenterology and Hepatology Y2 - 2018 KW - N2 - Outcomes for patients with sarcoma remain poor with overall survival for patients in the metastatic setting typically in the range of 12 to 18 months (1). Programmed death 1 protein (PD-1) has become one of the most important targets in cancer immunotherapy (2), particularly for the many inflammatory cancers that contain PD-1 expressing T cells or cells expressing its ligand (PD-L1) (3). While recent studies have shown that some sarcoma patients may respond to PD-1 blockade, responses are highly subtype specific. Even in highly inflammatory subtypes such as undifferentiated pleomorphic sarcoma (UPS), responses are only seen in a minority of patients demonstrating the need for combination therapies that further improve patient outcome (4). UR - https://tgh.amegroups.org/article/view/4070